Glucose metabolism in normoglucaemic haemodialysis patients: a possible role for biotin?
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to B Agroyannis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The efficacy and safety of acipimox, an antilipolytic agent, were studied in 10 uremic patients under hemodialysis (group A) and in 8 renal transplant recipients with adequate renal function (group B). The medication was given for 20 weeks at a dose of 250 mg daily in both groups. Total serum cholesterol decreased significantly from 218.1 +/- 17.4 to 175.2 +/- 15.2 mg/dL (-19.7%) in group A and from 261.2 +/- 16.5 to 215.3 +/- 26.9 mg/dL (-17.6%) in group B; as did serum triglycerides, from 206.7 +/- 26.9 to 146.9 +/- 17.6 mg/dL (-29%) in group A and from 168.2 +/- 20.6 to 111.3 +/- 12.4 mg/dL (-33.8%) in group B. Low-density lipoprotein (LDL)-cholesterol and very low-density lipoprotein (VLDL)-cholesterol were also decreased significantly (LDL-C by -27% and -25%, and VLDL-C by -29.2% and -33.8% in groups A and B, respectively). Furthermore, the high-density lipoprotein (HDL)-cholesterol was increased significantly, by +29.6% in group A and +18% in group B. The apolipoproteins Apo-A1 and Apo-A2 were decreased in Group A but not in group B. The Apo-B was decreased in group B. Serum CPK (total and muscle fraction), total bilirubin, SGPT, SGOT, alkaline phosphatase, gamma GT, LDL, a-Fp, and creatinine remained unchanged in both groups. Acipimox seems to be effective in the regulation of atherogenic lipid disorders in hemodialysis patients and renal transplant recipients, without any muscular damage or alteration of kidney and liver function.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Serum transferrin and ceruloplasmin were measured in 27 healthy women as well as in 21 women who received fractionated radiation therapy (RT) after undergoing surgery for cervical or uterine carcinoma. Although no significant difference in the mean values of transferrin was found between the healthy women and the patients before the initiation of RT, a significantly lower concentration of transferrin after the end of RT (p < 0.001) was observed in comparison to that of controls and of patients before RT. On the contrary, a significantly higher serum concentration of ceruloplasmin was found in patients before and after RT compared to that in healthy women (p < 0.001). The observed increase of ceruloplasmin after RT was not found to be significantly different from the mean value before RT. In conclusion serum transferrin is reduced by RT, while ceruloplasmin which is higher in patients before RT shows a tendency for increase following RT.
Normally the differences in arterial-venous pH (A-VpH) and veno-arterial pCO2 (V-ApCO2) are small and constant. This study deals with A-VpH and V-ApCO2 and their effect on arterial-venous saturation hemoglobin percentage (A-VSHb%) in uremic patients under hemodialysis (HD). In 17 uremic patients under HD with acetate, blood samples were collected anaerobically in heparinized syringes from artery (fistula) and vein (forearm without fistula) pre- and post-HD. In these samples pH, pCO2 and SHb% were determined and A-VpH, V-ApCO2 and A-VSHb% were estimated. Comparison between the values pre- and post-HD of A-VpH, V-ApCO2 and A-VSHb% shows that these three values were decreased significantly post-HD (p < 0.001). The correlation of all values (pre- and post-HD) of A-VpH and V-ApCO2 with that of A-VSHb% was significant and positive (r = 0.514 p < 0.01, r = 0.505 p < 0.01, respectively).
Explore the source record for details and available documents.
Serum changes of Ferroxidase I and II well as the total iron binding capacity (TIBC) and unsaturated iron binding capacity (UIBC) were measured throughout their gestation in 32 normal pregnant women. Significantly higher concentrations for all the above mentioned parameters were found as pregnancy advanced. Moreover, a significant and positive correlation between the weeks of gestation and a) serum Ferroxidase I (r:0.568 p < 0.001), d) serum Ferroxidase II (r:0.619 p < 0.001), c) serum TIBC (r:0.549 p < 0.01), and d) serum UIBC (r:0.424 p < 0.05) was found. The parallel serum changes of both ferroxidase with those of TIBC and UIBC are also shown in this study. The correlation of Ferroxidase I with TIBC (r:0.734 p < 0.001) and UIBC (r:0.536 p < 0.01) as that of Ferroxidase II with TIBC(r:0.634 p < 0.001) and UIBC (r:0.513 p < 0.01) was significant and positive. In conclusion, serum Ferroxidase I and II are progressively increased with serum TIBC and UIBC as pregnancy advances.
Explore the source record for details and available documents.
Successful renal transplantation has a favourable effect on the development of ocular disorders in periodic haemodialysis patients. Certain complications arise in the eyes of the recipients and are attributed mainly to the immunosuppressive medication. The purpose of our study was the recording of the ocular complications in patients with successful renal transplants after long-term stabilization of renal function and immunosuppressive therapy.
Explore the source record for details and available documents.
In several studies in humans and animals it has been suggested that high osmolality and ionicity of contrast media are responsible for higher nephrotoxicity. To examine this suggestion, we evaluated the renal effects of three different contrast media--an ionic high osmolar, an ionic low osmolar, and a nonionic--following intravenous and renal arterial administration, in a population of 84 unselected, nondiabetic patients with adequate renal function. The results showed that the nephrotoxicity is minimal and equal for all three contrast media and for both routes of their administration, and it is concluded that in this category of patients the far higher cost of the newer low osmolar ionics and nonionics should be considered seriously in regard to nephrotoxicity.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We studied the feasibility of treating refractory anemia and post-transfusional serious hemochromatosis in a patient undergoing hemodialysis (3x4 h weekly) for fourteen years, with recombinant human erythropoietin (r-HuEPO) associated with blood-letting. Blood transfusion previously received by the patient at a rate of two units of packed red cells every month for nine years was stopped and r-HuEPO (80 U/kg b.w.) was administered i.v. at the end of each hemodialysis. When Hct increased over 30%, approximately 40 ml of blood was removed per hemodialysis session in an attempt to accelerate iron loss. Excellent control of anemia and hemochromatosis was achieved after seven months of treatment. The patient's general condition and skin pigmentation were significantly improved.